Healthtech Solutions (OTC: HLTT), focused on acquiring and investing in strategic cutting-edge health care technological opportunities, recently expanded its portfolio in a move that facilitated entry into the precision cancer care market. Varian Bio was added to the Healthtech Solutions’ umbrella via the parent company acquiring a wholly owned subsidiary, Healthtech Oncology Inc., which will own a 100% interest in Varian Bio. This move adds Varian Bio to HLTT’s growing portfolio to join MediScan Inc., a developer of technology that converts 2D images from portable ultrasound machines into digital 3D images, and RevHeart, a company advancing critical research into the treatment of COVID-related heart muscle injury. “Varian is in the pre-clinical stages of developing two aPKC iota inhibitors in user-preferred delivery methods to treat cancer. VAR-101 is being designed as a topical formulation for the treatment of basal cell carcinoma, the most common type of skin cancer, with about 3.6 million diagnoses each year in the U.S.,” reads a recent article. “VAR-102 is an oral formulation being developed for treating an array of solid tumors where there is existing evidence aPKCi inhibition would be beneficial, such as pancreatic, colorectal and non-small cell lung cancers (“NSCLC”). These indications represent areas of unmet need, as the fourth, third and second leading cause of cancer deaths, respectively, in the U.S. annually.”
To view the full article, visit https://nnw.fm/q1zM1
About Healthtech Solutions Inc.
Healthtech Solutions is a reporting public company. The board of directors is focusing the company’s resources into creating a platform to acquire and/or invest in cutting-edge health care technology in the medical device biopharma and pharmaceutical fields. The goal is to bring these solutions to market.
To date, Healthtech Solutions has invested in three areas of medical technology breakthrough:
- MediScan Inc., which is developing a technology that converts 2D images from a portable ultrasound machine into digital 3D images to provide better diagnosis and more accurate internal trauma views. The goal is a commercial system that can provide the data equivalent to an X-ray, MRI or CT scan, without radiation and at a lower cost.
- RevHeart Inc., which is advancing critical research into the treatment of COVID-related heart muscle injury.
- Varian Biopharmaceutical Inc., a precision oncology company, is the first acquisition of Healthtech Oncology Inc.
Healthtech Solutions has a pipeline of additional acquisitions currently under due diligence.
NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at https://nnw.fm/HLTT
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork